The present invention relates to a new use of a statin drug in the improvement
of diabetic neuropathy, specifically in improving nerve conduction velocity and
nerve blood flow in patients suffering diabetes, in particular to pharmaceutical
combinations of the statin drug and other agents known to improve diabetic neuropathy
such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE)
inhibitor or an angiotensin II (AII) antagonist which combinations are useful in
the prevention and treatment of the complications of diabetes.
